Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: results from ms paths

被引：0
|
作者：
Hersh, C. [1 ]
Kieseier, B. [2 ]
De Moor, C. [2 ]
Miller, D. [3 ]
Campagnolo, D. [2 ]
Williams, J. [2 ]
Fitzgerald, K. [4 ]
Xiong, K. [2 ]
Mcginley, M. [3 ]
Hyland, M. [5 ]
Rudick, R. [2 ]
Ziemssen, T. [6 ,7 ]
Koulinska, I. [2 ]
机构：
[1] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Mellen Program MS, Las Vegas, NV USA
[2] Biogen, Cambridge, MA USA
[3] Cleveland Clin, Mellen Ctr, Cleveland, OH 44106 USA
[4] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[5] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14627 USA
[6] Univ Clin Carl Gustav Carus, Multiple Sclerosis Ctr, Dresden, Germany
[7] Univ Clin Carl Gustav Carus, Neuroimmunol Lab, Dresden, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1036
引用
收藏
页码：609 / 609
页数：1
相关论文
共 50 条
  • [21] Treatment of multiple sclerosis with natalizumab: experiences from a real-life cohort over 15 years
    Auer, M.
    Zinganell, A.
    Hegen, H.
    Bsteh, G.
    Di Pauli, F.
    Berek, K.
    Fava, E.
    Wurth, S.
    Berger, T.
    Deisenhammer, F.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 588 - 588
  • [22] Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
    Auer, Michael
    Zinganell, Anne
    Hegen, Harald
    Bsteh, Gabriel
    Di Pauli, Franziska
    Berek, Klaus
    Fava, Elena
    Wurth, Sebastian
    Berger, Thomas
    Deisenhammer, Florian
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [23] Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
    Michael Auer
    Anne Zinganell
    Harald Hegen
    Gabriel Bsteh
    Franziska Di Pauli
    Klaus Berek
    Elena Fava
    Sebastian Wurth
    Thomas Berger
    Florian Deisenhammer
    Scientific Reports, 11
  • [24] Real-world outcomes of siponimod in multiple sclerosis patients
    Tan, Hongmei
    Quan, Chao
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1129 - 1129
  • [25] Impact of ibrutinib on quality of life in patients with chronic lymphocytic leukemia: preliminary results of real-world experience
    Osorio, Maria J. Mela
    Pavlovsky, Astrid
    Pavlovsky, Carolina
    Fernandez, Isolda
    Massa, Federico Sackmann
    Ferrari, Luciana
    Juni, Mariana
    Riddick, Maximiliano
    Pavlosky, Miguel
    LEUKEMIA & LYMPHOMA, 2020, 61 : 195 - 197
  • [26] A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study
    Gauer, L.
    Bigaut, K.
    Berger, E.
    Debouverie, M.
    Moreau, T.
    de Seze, J.
    REVUE NEUROLOGIQUE, 2023, 179 (06) : 576 - 584
  • [27] Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry
    Guger, Michael
    Enzinger, Christian
    Leutmezer, Fritz
    Kraus, Joerg
    Kalcher, Stefan
    Kvas, Erich
    Berger, Thomas
    JOURNAL OF NEUROLOGY, 2019, 266 (11) : 2672 - 2677
  • [28] Real-World Use of Wearable Devices in a Large Multiple Sclerosis Cohort
    Foschini, Luca
    Medin, Jennie
    Bezlyak, Vladimir
    Stuck, David
    Silva, Diego
    Lee, Wei-Nchih
    NEUROLOGY, 2018, 90
  • [29] A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis
    Herman, Jorge Acevedo
    Khalighinejad, Farnaz
    York, Katherine
    Radu, Irina
    Morales, Idanis Berrios
    Ionete, Carolina
    Hemond, Christopher C.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 47
  • [30] Quality of life (QoL) in multiple sclerosis (MS) patients
    Carpentras, G.
    Pugliatti, M.
    JOURNAL OF PSYCHOPHYSIOLOGY, 2006, 20 (03) : 218 - 218
12345